About The Webinar
The Cunningham Panel™ is an aid in a clinician’s diagnosis of autoimmune encephalopathy and basal ganglia encephalitis disorders. Neurologic, psychiatric, and behavioral symptoms can result from a number of different etiologies. When the underlying root is an autoimmune encephalopathy or basal ganglia encephalitis, treatments that have shown effectiveness include anti-infectives, anti-inflammatory and immune modulatory modalities.
This free educational webinar will explain the clinical significance of autoimmune antibodies against brain and neuronal targets, and the types of symptoms that have been associated with them. We will review some of the most common presenting symptoms associated with positive Cunningham Panel™ results, and share published clinical data on patients’ before and after effective treatment.
Attendees will gain a strong understanding of the biology behind infection-triggered autoimmune neuropsychiatric disorders, the most common patient symptoms, and how to utilize the Cunningham Panel™ test results in treatment decisions.
Webinar Schedule
- Friday, December 15 at 12pm CT
This webinar is intended only for Medical Professionals.
The webinar content has been made available for informational purposes only. The information provided is not intended to be medical or healthcare advice for any individual medical problem, nor a substitute for medical or professional advice and services from a qualified healthcare provider.
By attending or viewing the webinar, you acknowledge and agree that we have not represented that any content provided in this webinar has the ability to diagnose a medical condition, prescribe treatment, or perform any other tasks that constitute the practice of medicine.
Moleculera hereby disclaims any and all liability to any party for any direct, indirect, implied, punitive, special, incidental, or other consequential damages arising directly or indirectly from any use of the webinar content, which is provided as is, and without warranties.
All rights reserved. No part of this presentation may be reproduced, distributed, or transmitted in any form or by any means, including recording, photocopying, or other electronic or other methods without the prior written consent of the publisher.
WEBINAR PRESENTER
Dr. Craig Shimasaki, PhD, MBA
Dr. Shimasaki received his BS in Biochemistry from the University of California at Davis, his PhD in Molecular Biology and Biotechnology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma and is the cofounder and CEO of Moleculera Labs, a neuroimmunology precision medicine company focused on identifying the underlying roots of neurologic, psychiatric, and behavioral disorders triggered by an autoimmune response. He has spent over 35 years working in the fields of molecular biology, viral pathogenesis, and infection-triggered autoimmune neuropsychiatric disorders.
Dr. Shimasaki started his career at Genentech and has worked across all stages of research, development, clinical trials, and regulatory approval of technology innovation from bench-to-bedside. His research work includes epitope mapping of HIV proteins, genetic-based predictors of breast cancer risk, influenza and RSV diagnostics and therapeutics, and the pathogenesis of infection-triggered neuropsychiatric disorders. He has co-founded multiple companies and led multiple products through the FDA approval process and is a co-inventor on multiple patents. Internationally, he teaches and mentors scientists, physicians and biotech leaders on how to translate their research into acutely needed medical interventions. His passion is to translate scientific discoveries into acutely needed products so that more patients can live longer, healthier lives.
WEBINAR HOST
Amy Cross, RN
Medical Relations Manager
Moleculera Labs